Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Cutler

Showing results (191-200 of 217) with videos related to

Pageof 22
Sort By:
Cancer Investigation|October 21, 2011
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancerNan Soon Wong, Kellen L Meadows, Lee S Rosen, et al.
Pain|April 27, 2001
Orexin-A, an hypothalamic peptide with analgesic propertiesS Bingham, P T Davey, A J Babbs, et al.
Journal of Clinical Immunology|September 1, 1996
Clinical, hematologic, and immunologic effects of interleukin-10 in humansA C Fuchs, E V Granowitz, L Shapiro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2022
Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast CancerHope S Rugo, Gerardo A Umanzor, Francisco J Barrios, et al.
Clinical and Translational Science|March 26, 2018
Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of ErtugliflozinSangeeta Raje, Ernesto Callegari, Vaishali Sahasrabudhe, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|June 19, 2018
A Randomized Controlled Trial of Balloon Dilation as a Treatment for Persistent Eustachian Tube Dysfunction With 1-Year Follow-UpTed A Meyer, Ellen M O'Malley, Rodney J Schlosser, et al.
British Journal of Clinical Pharmacology|May 7, 2021
Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic studyChristopher G C A Jackson, Tak Hung, Eva Segelov, et al.
Therapeutic Advances in Medical Oncology|July 26, 2023
Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity studyMing-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, et al.
Nature Medicine|March 29, 2019
Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancersConan G Kinsey, Soledad A Camolotto, Amelie M Boespflug, et al.
Nature Medicine|March 6, 2019
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancersConan G Kinsey, Soledad A Camolotto, Amelie M Boespflug, et al.
Pageof 22

Showing results (191-200 of 217) with videos related to

Sort By:
Pageof 22
Cancer Investigation|October 21, 2011
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancerNan Soon Wong, Kellen L Meadows, Lee S Rosen, et al.
Pain|April 27, 2001
Orexin-A, an hypothalamic peptide with analgesic propertiesS Bingham, P T Davey, A J Babbs, et al.
Journal of Clinical Immunology|September 1, 1996
Clinical, hematologic, and immunologic effects of interleukin-10 in humansA C Fuchs, E V Granowitz, L Shapiro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2022
Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast CancerHope S Rugo, Gerardo A Umanzor, Francisco J Barrios, et al.
Clinical and Translational Science|March 26, 2018
Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of ErtugliflozinSangeeta Raje, Ernesto Callegari, Vaishali Sahasrabudhe, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|June 19, 2018
A Randomized Controlled Trial of Balloon Dilation as a Treatment for Persistent Eustachian Tube Dysfunction With 1-Year Follow-UpTed A Meyer, Ellen M O'Malley, Rodney J Schlosser, et al.
British Journal of Clinical Pharmacology|May 7, 2021
Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic studyChristopher G C A Jackson, Tak Hung, Eva Segelov, et al.
Therapeutic Advances in Medical Oncology|July 26, 2023
Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity studyMing-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, et al.
Nature Medicine|March 29, 2019
Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancersConan G Kinsey, Soledad A Camolotto, Amelie M Boespflug, et al.
Nature Medicine|March 6, 2019
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancersConan G Kinsey, Soledad A Camolotto, Amelie M Boespflug, et al.
Pageof 22